Caroline Polisi is a federal and white-collar criminal defense attorney in New York City and a lecturer in law at Columbia Law School. She frequently appears on CNN as a legal analyst and is featured on this season of “The Dropout: Elizabeth Holmes on Trial.” Follow her on Twitter @CarolinePolisi. The views expressed in this commentary are her own. Read more opinion articles on CNN. Elizabeth Holmes, Silicon Valley’s one-time darling for founding and leading the now failed biotech company Theranos, is on trial in one of the most highly anticipated criminal fraud cases in the country — and one of her potential defense strategies is not what you might expect. At the age of 32, Holmes was dubbed the “youngest self-made woman billionaire” by Forbes. Her revolutionary biotech startup, Theranos, had a market valuation of over $9 billion, and was by all accounts the elusive Silicon Valley unicorn: a company promising to democratize the health care system through proprietary blood diagnostic technology. Holmes boasted the ability to do an array of blood tests from a single finger pinprick with just a few drops of blood, and claimed she could do it better, quicker, and cheaper than traditional blood testing. Except she couldn’t. By the time The Wall Street Journal published a scathing investigation into the company’s practices and Holmes’ integrity in 2015, it was too late. Theranos was already sending blood tests to third-party vendors using traditional blood diagnostic analysis because its own technology was not up to snuff. In 2017, Theranos settled a civil lawsuit with Walgreens for an undisclosed amount and reached a deal with investors in exchange for them releasing potential legal claims against the company. By 2018, I wrote that I wouldn’t be surprised if the United States Attorney’s Office for the Northern District of California had an open criminal investigation against Holmes. Turns out it did. Holmes is now facing 12 fraud charges and is accused of engaging in a criminal conspiracy with former Theranos chief operating officer and president Ramesh “Sunny” Balwani. Holmes and Balwani allegedly lied about the capabilities of Theranos’ proprietary technology, the extent of commercial and business relationships, its access to the Department of Defense, and the financial state of the company. Both have pleaded not guilty and are being tried separately. Over the course of pretrial litigation, glimpses of a potentially explosive defense began to take shape. Holmes’ team noted in court filings that they may utilize an expert in clinical psychology whose work focuses on trauma and victimization as well as Post-Traumatic Stress Disorder. Moreover, they alleged that Balwani was more than just Theranos’ COO and Holmes’ co-defendant.
All data is taken from the source: http://us.cnn.com
Article Link: https://us.cnn.com/2021/09/11/opinions/elizabeth-holmes-trial-theranos-polisi/index.html
#holmes #newsmax #newsworldabc #newsworldbbc #newsworldfox #newstodaycnn #